Bispecifics Take Centre Stage as Next Wave of Oncology Innovation Accelerates Post-ASCO 2026
Momentum behind bispecific and multispecific therapeutics has reached a new inflection point, with recent clinical and pipeline developments underscoring their growing role in reshaping the oncology landscape.
Recent data readouts and conference highlights have reinforced the rapid evolution of the field. Breakthroughs in targeted approaches, including RAS pathway inhibition in pancreatic cancer and the continued advancement of CD3-based bispecifics, signal a new era of precision-driven immuno-oncology.
At the same time, major players such as BioNTech and Bristol Myers Squibb are pushing multispecific formats deeper into solid tumours, while emerging innovators like YZYBIO and Formosa Pharmaceuticals continue to expand the breadth of novel candidates entering clinical evaluation.
Collectively, these developments reflect a clear industry shift. Bispecific antibodies are no longer an emerging modality. They are fast becoming a cornerstone of next generation cancer therapy.
The Challenge Ahead
While the recent wave of clinical data has generated significant excitement, key scientific and translational challenges remain.
Questions around durability of response, safety optimisation, and effective solid tumour targeting continue to define the path forward.
Addressing the Next Phase
These critical hurdles will take centre stage at the upcoming World Bispecific Summit Europe, bringing together leading experts from across pharma and biotech, including: Genmab, Merus, Roche, Sanofi, Zymeworks, Biomunex, and more.
Across three days of in-depth discussion and collaboration, the summit will focus on:
🔷 Advancing solid tumour translation: Overcoming immunosuppressive microenvironments
🔷 Engineering next-gen T-cell engagers: Maximising efficacy without triggering toxicity
🔷 Unlocking advanced formats: Tri-specifics, masked antibodies, and conditionally active designs
🔷 Optimising PK/PD profiles: Extending therapeutic windows and improving outcomes
🔷 Enhancing preclinical models: Predicting clinical success earlier and more reliably
A Defining Moment for the Field
As the industry looks beyond recent clinical milestones, the focus now shifts to translating early promise into durable, scalable success.
The World Bispecific Summit Europe provides a critical platform for these conversations, uniting the leaders, innovators, and decision-makers driving the next chapter of bispecific development.
If bispecifics are part of your pipeline, or your future strategy, this is where the next wave of innovation will be defined.
Explore the Full Event Guide
- Hear from 25+ world-class speakers across pharma and biotech sharing cutting-edge data on bispecific antibodies, T-cell engagers, and next-generation multispecific formats advancing toward clinical success
- Connect with 60+ senior attendees driving innovation in solid tumour targeting, immune cell redirection, and next-generation engineering strategies
- Gain insights from 20+ data-driven presentations covering translational challenges, safety optimisation, potency enhancement and strategies to improve clinical durability
- Take part in a dedicated Scientific Poster Session, spotlighting novel targets, platform technologies, and preclinical-to-clinical translation data
- Unlock 7+ hours of high-value networking, designed to foster strategic collaborations, partnerships, and pipeline acceleration
